EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, FEBRUARY 4, 2021
Media advisory: The full article is linked to this news release. A visual abstract is below.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.7442?guestAccessKey=32dca14c-423c-4b79-af71-12de4d1590b9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020421
What The Study Did: This randomized clinical trial looked at changes in levels of the hormone estradiol in men with hormone receptor–positive breast cancer after three months of treatment with endocrine therapies.
Authors: Sibylle Loibl, M.D., Ph.D., of the German Breast Group in Neu-Isenburg, Germany, is the corresponding author.
Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.